China-based startups Porton Advanced Solutions and Yinjia (Shanghai) Biosciences Co. have announced a strategic partnership in developing core protein raw materials for cell and gene therapy (CGT) and test reagent products for quality control and evaluation systems to accelerate the development and commercialization of CGT.

Porton Advanced contract development and manufacturing organisation (CDMO) offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy. Yinjia Biosciences focuses on high-quality core protein raw materials and also offers companion diagnostics products for innovative adjuvant therapies.

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems. Porton Advanced will continue to advance its technology and capabilities to accelerate the development of CGT to meet clinical needs and empower global partners.

"This strategic partnership will strengthen Porton Advanced's CGT CDMO and accelerate the development of innovative CGT therapeutics to deliver life-changing benefits to patients," said Dr Wang Yangzhou, CEO of Porton Advanced.